MedPlus
MedPlus Health Services Limited

Date: 14th February, 2022

BSE Limited
Phiroze Jeejebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

National Stock Exchange of India Limited
Exchange Plaza , 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai - 400051

Dear Sir/Madam,

Sub: Outcome of Board Meeting of MedPlus Health Services Limited held on 14th February, 2022

This is to inform you that the Board of Directors of the Company at its Meeting held on 14th February, 2022 have approved the Unaudited Standalone and Consolidated Financial Results of the Company for the Third Quarter and Nine months ended 31st December, 2021.

This is an intimation under Regulations 30, 33, 51 and 52 read with para A. 4. h) of Part A and para A. (16) (b) of Part B of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

We are enclosing the Unaudited Standalone and Consolidated Financial Results of the Company for the Third Quarter and Nine months ended 31st December, 2021, along with the Limited Review Report thereon, issued by the Statutory Auditors, M/s B S R & Associates LLP, Chartered Accountants.

The Meeting of the Board of Directors of the Company commenced at 5.30 p.m. and concluded at 7.00 p.m.

This intimation is also being uploaded on the Company's website at www.medplusindia.com.

You are requested to kindly note the same.

This is for your information.

For and on behalf of MedPlus Health Services Limited

Shilpi Keswani
Company Secretary & Compliance Officer

MEDPLUS HEALTH SERVICES LIMITED HYDERABAD

Encl: a/a

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on unaudited standalone financial results of MedPlus Health Services Limited for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of MedPlus Health Services Limited ("the Company") for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 ("the Statement").

   Attention is drawn to the fact that the figures for the quarter ended 30 September 2021,corresponding quarter ended 31 December 2020 and the corresponding period from 01 April 2020 to 31 December 2020, as reported in these unaudited standalone financial results have been approved by the Company's Board of Directors, but have not been subjected to review since the requirement of submission of quarterly standalone financial results is applicable on listing of equity shares of the Company during the quarter ended 31 December 2021.

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above , nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP**
Chartered Accountants
Firm's Registration No.:116231W/W-100024

Arpan Jain

Arpan Jain
Partner
Membership No.: 125710
UDIN:22125710ACACGJ3419

Hyderabad
14 February 2022

MedPlus Health Services Limited (formerly known as MedPlus Health Services Private Limited)

Regd. Office: 707, 7th Floor, 5-9-13 Taramandal Commercial Complex, Saifabad, Hyderabad - 500004, Telangana, India

CIN - U85110TG2006PLC051845

Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended December 31, 2021

(INR in Millions)

S.No.	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2021	September 30, 2021	December 31, 2020	December 31, 2021	December 31, 2020	March 31, 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
	Revenue from operations	247.11	561.98	205.73	1,068.94	515.65	683.10
	Other income	11.22	12.18	5.36	33.30	14.08	21.10
I	**Total Income**	**258.33**	**574.16**	**211.09**	**1,102.24**	**529.73**	**704.20**
	Expenses						
	Cost of materials consumed	35.50	72.93	16.19	141.85	73.40	94.65
	Purchases of stock-in-trade	177.13	296.34	122.21	763.13	297.61	412.21
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(18.10)	103.75	6.42	(34.26)	4.18	(6.64)
	Employee benefits expense	40.15	25.90	24.65	94.72	204.47	225.75
	Finance costs	6.35	6.07	1.38	14.45	2.94	5.65
	Depreciation and amortisation expense	12.41	10.13	2.75	27.69	8.19	13.15
	Other expenses	17.03	23.40	10.97	48.10	26.09	45.10
II	**Total expenses**	**270.47**	**538.52**	**184.57**	**1,055.68**	**616.88**	**789.87**
III	**Profit before tax (I-II)**	**(12.14)**	**35.64**	**26.52**	**46.56**	**(87.15)**	**(85.67)**
	Tax expense						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	-	-	-	-	-	-
IV	**Total tax expense**	-	-	-	-	-	-
V	**Net Profit/(Loss) after tax (III-IV)**	**(12.14)**	**35.64**	**26.52**	**46.56**	**(87.15)**	**(85.67)**
	Other Comprehensive Income						
	(i) Items that will not be reclassified to profit or loss						
	- Net actuarial gain / (loss) on define benefit plan	(0.16)	0.53	(1.49)	0.38	2.30	2.91
	(ii) Income tax relating to items that will not be reclassified to profit and loss	-	-	-	-	-	-
VI	**Other comprehensive income/(Expense) for the period, net of tax**	**(0.16)**	**0.53**	**(1.49)**	**0.38**	**2.30**	**2.91**
VII	**Total comprehensive Income/(Expense) for the period (V+VI)**	**(12.30)**	**36.17**	**25.03**	**46.94**	**(84.85)**	**(82.76)**
VIII	**Paid-up Capital**						
	(i) Equity Share Capital	**238.60**	**64.39**	**1.94**	**238.60**	**1.94**	**4.48**
	(ii) Compulsorily Convertible Preference Shares ('CCPS')	-	**316.25**	**0.61**	-	**0.61**	**437.88**
IX	**Other Equity**						**5170.32**
X	**Earnings per equity share**	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Annualised)
	Basic earnings per share (Rs.)	(0.11)	0.32	0.26	0.42	(0.84)	(0.82)
	Diluted earnings per share (Rs.)	(0.11)	0.32	0.25	0.42	(0.81)	(0.79)
XI	**Face value per share**						
	Equity shares	2.00	2.00	2.00	2.00	2.00	2.00
	CCPS considered as equity	-	20.00	20.00	-	20.00	20.00

For MEDPLUS HEALTH SERVICES LIMITED

Chief Executive & Managing Director

MEDPLUS HEALTH SERVICES LIMITED HYDERABAD

Notes to the Unaudited standalone financial results:

1 The above reviewed unaudited standalone financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on February 14, 2022.These financial results have been subjected to review by the Statutory Auditors of the Company and the auditors have expressed an unmodified opinion on the same.

2 The Company has completed its Initial Public Offer ('IPO') and listed its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE') on December 23, 2021. The accompanying financial results are the first financial results of the Company post its listing. Accordingly, the figures for the quarter ended September 30, 2021 and quarter and nine months ended December 31, 2020 as reported in these financial results were neither reviewed nor subject to audit, However, the management has exercised necessary due diligence to ensure that the financial results for these periods provide a true and fair view of the Company's affairs.

3 The Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 Million and an offer for sale of 7,826,626 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. The Company has incurred Rs. 635.28 million as IPO related expenses which are proportionately allocated between the Company and Selling Shareholders as per respective offer size. The Company's share of these expenses amounting to Rs. 258.34 million has been adjusted against Securities Premium. Subsequently on 23rd December 2021, the equity shares of the Company have been listed on the BSE Limited and National Stock Exchange of India Limited. As at December 31 2021, the whole IPO proceeds were lying in the Company's bank account.

4 The management believes that the outbreak of COVID pandemic does not have any significant impact on the future operations of the Company since it provides essential services i.e., pathological testing services and sale of pharmaceutical items. Accordingly, the company continues to prepare the financial results on a going concern basis. Basis management's current assessment, it does not expect any adjustments to the carrying amounts of inventories, tangible assets, intangible assets, trade receivables and other financial assets on account of the current economic situation. The eventual outcome of the impact of this global health pandemic may be different from those estimated as on the date of approval of these standalone financial results.

5 The Company has granted 70,317 ESOPs to its employees and 865,587 to the employees of its subsidiaries under Employee stock option and Share plan 2021 after taking necessary approval at an exercise price of Rs 232 per option on 22nd November 2021. These options will vest over a period of 1-4 years. Accordingly, the company has recorded a cost of INR 4.97 million during the quarter ended 31 December 2021.

6 During the quarter ended 31 December 2021,the Company has approved and converted the Compulsory convertible preference shares of Series A, Series B, Series B1, Series B2, Series C1 and Series C2 into equity shares of the Company in the ratio of 1:5.

7 As per Ind AS 108 'Operating segments', the Company has disclosed the segment information only as part of the consolidated financial results.

8 Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April 2021.

9 The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

Place: Hyderabad
Date: 14 February 2022

For and on behalf of the Board of Directors of
MedPlus Health Services Limited
(formerly known as MedPlus Health Services Private Limited)

G.Madhukar Reddy
Managing Director
DIN: 00098097

MEDPLUS HEALTH SERVICES LIMITED
HYDERABAD

B S R & Associates LLP
Chartered Accountants

Salarpuria Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited Review Report on unaudited consolidated financial results of MedPlus Health Services Limited for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of MedPlus Health Services Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2021 and year-to-date results for the period from 01 April 2021 to 31 December 2021 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

   Attention is drawn to the fact that the figures for the quarter ended 30 September 2021, corresponding quarter ended 31 December 2020 and the corresponding period from 01 April 2020 to 31 December 2020, as reported in these unaudited consolidated financial results have been approved by the Parent's Board of Directors, but have not been subjected to review since the requirement of submission of quarterly consolidated financial results is applicable on listing of equity shares of the company during the quarter ended 31 December 2021.

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Statement includes the interim financial results of eleven Subsidiaries which have not been reviewed, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs. 2,986.65 Million and 8,668.55 Million, total net profit after tax (before consolidation adjustments) of Rs. 22.73 Million and Rs. 76.53 Milllion and total comprehensive income (before consolidation adjustments) of Rs. 22.68 Million and Rs 76.18 Milion for the quarter ended 31 December 2021 and for the period from 01 April 2021 to 31 December 2021 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

   Our conclusion is not modified in respect of this matter.

For **B S R & Associates LLP**
Chartered Accountants
Firm's Registration No.:116231W/W-100024

Arpan Jain

Arpan Jain
Partner
Membership No.: 125710
UDIN:22125710ACAHYB7622

Hyderabad
14 February 2022

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Optival Health Solutions Private Limited	Subsidiary
2	MHS Pharmaceuticals Private Limited	Subsidiary
3	NovaSud Pharmaceuticals Private Limited	Subsidiary
4	Wynclark Pharmaceuticals Private Limited	Subsidiary
5	Sai Sridhar Pharma Private Limited (Subsidiary of NovaSud Pharmaceuaticals Private Limited)	Subsidiary
6	Venkata Krishna Enterprises Private Limited (Subsidiary of NovaSud Pharmaceuaticals Private Limited)	Subsidiary
7	Deccan Medisales Private Limited (Subsidiary of NovaSud Pharmaceuaticals Private Limited)	Subsidiary
8	Shri Banashankari Pharma Private Limited (Subsidiary of NovaSud Pharmaceuaticals Private Limited)	Subsidiary
9	Sidson Pharma Distributors Private Limited (Subsidiary of NovaSud Pharmaceuaticals Private Limited)	Subsidiary
10	Clearancekart Private Limited	Subsidiary
11	Agilemed Investments Private Limited (upto December 4, 2020)	Subsidiary
12	Kalyani Meditimes Private Limited	Subsidiary

MedPlus Health Services Limited (formerly known as MedPlus Health Services Private Limited)

Regd. Office: 707, 7th Floor, 5-9-13 Taramandal Commercial Complex, Saifabad, Hyderabad - 500004, Telangana, India

CIN - U85110TG2006PLC051845

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021

(Rs. in Millions)

S.No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December 2021	30 September 2021	31 December 2020	31 December 2021	31 December 2020	31 March 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
	Revenue from operations	9,334.53	9,247.38	8,009.88	28,133.72	22,635.43	30,692.69
	Other income	73.34	67.70	87.84	183.14	171.98	215.45
I	**Total income**	9,407.87	9,315.08	8,097.72	28,316.86	22,807.41	30,908.14
	Expenses						
	Cost of materials consumed	35.79	(32.30)	31.17	142.68	88.67	90.85
	Purchases of stock-in-trade	7,721.59	7,013.16	6,751.19	23,019.00	18,557.23	25,213.88
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(360.99)	409.62	(384.12)	(938.02)	(802.82)	(1054.40)
	Employee benefits expense	1,003.60	913.23	796.33	2,801.72	2,596.46	3,386.51
	Finance costs	165.31	160.82	131.30	478.51	402.11	548.45
	Depreciation and amortisation expense	304.84	276.80	218.67	852.46	640.72	882.70
	Other expenses	320.22	322.31	233.17	907.41	632.25	889.17
II	**Total expenses**	9,190.36	9,063.64	7,777.71	27,263.78	22,114.64	29,957.16
III	**Profit before tax (I-II)**	217.51	251.44	320.01	1,053.08	692.77	950.98
	Tax expense						
	- Current tax	62.02	60.11	92.58	267.69	231.55	306.55
	- Deferred tax	(13.68)	(8.75)	(0.16)	(47.45)	10.93	13.32
IV	**Total tax expense**	48.34	51.36	92.42	220.24	242.48	319.87
V	**Net Profit after tax (III-IV)**	169.17	200.08	227.59	832.84	450.29	631.11
	Other Comprehensive Income						
	(i) Items that will not be reclassified to profit or loss						
	- Net actuarial gain / (loss) on define benefit plan	(1.93)	12.17	(8.54)	21.89	7.53	11.51
	(ii) Income tax relating to items that will not be reclassified to profit and loss	0.44	(2.93)	1.13	(5.42)	(1.89)	(2.18)
VI	**Other comprehensive income/(Expense) for the period, net of tax**	(1.49)	9.24	(7.41)	16.47	5.64	9.33
VII	**Total comprehensive income (V+VI)**	167.68	209.32	220.18	849.31	455.93	640.44
VIII	**Profit for the period attributable to:**						
	Equity Holders of the Parent	171.73	203.13	229.09	840.74	455.05	638.58
	Non-controlling interest	(2.56)	(3.05)	(1.50)	(7.90)	(4.76)	(7.47)
		169.17	200.08	227.59	832.84	450.29	631.11
IX	**Total comprehensive income attributable to:**						
	Equity Holders of the Parent	167.85	212.37	221.68	854.82	460.68	647.93
	Non-controlling interest	(0.17)	(3.05)	(1.50)	(5.51)	(4.75)	(7.49)
		167.68	209.32	220.18	849.31	455.93	640.44
X	**Paid-up Capital**						
	(i) Equity Share Capital	238.60	64.39	1.94	238.60	1.94	4.48
	(ii) Compulsorily Convertible Preference Shares ('CCPS')	-	318.25	0.61	-	0.61	437.88
XI	**Other Equity**						7,301.06
XII	**Earnings per equity share**	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Annualised)
	Basic earnings per share (Rs.)	1.53	1.85	2.21	7.66	4.39	6.13
	Diluted earnings per share (Rs.)	1.52	1.82	2.12	7.44	4.21	5.88
XIII	**Face value per share**						
	Equity shares	2.00	2.00	2.00	2.00	2.00	2.00
	CCPS considered as equity	-	20.00	20.00	-	20.00	20.00

MEDPLUS HEALTH SERVICES LIMITED HYDERABAD

For MEDPLUS HEALTH SERVICES LIMITED

Chief Executive & Managing Director

Segment Information under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter and Nine months ended December 31, 2021

(Rs. In Millions)

Particulars	Quarter ended			Nine months ended		Year ended
	31 December 2021	30 September 2021	31 December 2020	31 December 2021	31 December 2020	31 March 2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment Revenue						
a. Wholesale	3,195.08	2,832.12	2,863.65	9,302.32	7,804.48	10,526.40
b. Retail	9,316.82	9,197.59	7,974.01	28,046.61	22,570.62	30,617.52
c. Pathology testing services	12.37	40.50	6.76	64.70	15.79	22.77
d. Unallocated	-	-	-	-	-	-
Total	**12,524.27**	**12,070.21**	**10,864.42**	**37,415.63**	**30,390.89**	**41,166.69**
Less: Inter Segment Revenue	3,189.74	2,822.83	2,854.54	9,281.90	7,755.46	10,474.00
Net sales/Income From Operations	**9,334.53**	**9,247.38**	**8,009.88**	**28,133.73**	**22,635.43**	**30,692.69**
2. Segment Results (Profit)(+)/ Loss (-) before tax and Interest from Each segment)						
a. Wholesale	0.68	0.49	1.39	1.96	2.58	2.88
b. Retail	401.08	387.42	439.58	1,492.12	1,056.47	1,455.11
c. Pathology testing services	(41.27)	9.10	(9.48)	(33.89)	(24.51)	(10.46)
d. Unallocated	-	-	-	-	-	-
Total	**360.49**	**397.01**	**431.49**	**1,460.19**	**1,034.54**	**1,447.53**
Less:						
(I)Finance cost	(165.92)	(160.38)	(129.93)	(476.49)	(396.75)	(548.45)
(ii) Interest Income	22.94	14.81	18.46	69.38	54.97	77.94
(iii)Other unallocable expenditure netoff (Unallocable income)	-	-	-	-	-	(26.05)
Total profit before tax	**217.51**	**251.44**	**320.02**	**1,053.08**	**692.76**	**950.97**
3. Segment assets						
a. Wholesale	6.16	4.86	7.00	6.16	7.00	38.84
b. Retail	16,894.30	16,459.50	14315.66	16894.30	14,315.66	13,669.77
c. Pathology testing services	665.63	296.89	193.91	665.63	193.91	75.80
d. Unallocated	6,523.36	703.70	-	6523.36	-	1,872.07
Total	**24,089.45**	**17,464.95**	**14,516.57**	**24,089.45**	**14,516.57**	**15,656.48**
4. Segment liabilities						
a. Wholesale	-	-	-	-	-	-
b. Retail	9,734.95	9,245.04	8324.64	9734.95	8,324.64	8,278.78
c. Pathology testing services	255.48	209.95	51.97	255.48	51.97	53.59
d. Unallocated	148.52	-	-	148.52	-	13.06
Total	**10,138.95**	**9,454.99**	**8,376.61**	**10,138.95**	**8,376.61**	**8,345.43**

For MEDPLUS HEALTH SERVICES LIMITED

Chief Executive & Managing Director

MEDPLUS HEALTH SERVICES LIMITED ★ HYDERABAD

Notes to the Unaudited consolidated financial results:

1. The above reviewed unaudited consolidated financial results of MedPlus Health Services Limited (formerly known as MedPlus Health Services Private Limited) ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Group at its meeting held on February 14, 2022.These financial results have been subjected to review by the Statutory Auditors of the Group and the auditors have expressed an unmodified opinion on the same.

2. The Company has completed its Initial Public Offer ('IPO') and listed its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE') on December 23, 2021. The accompanying financial results are the first financial results of the Company post its listing. Accordingly, the figures for the quarter ended September 30, 2021 and quarter and nine months ended December 31, 2020 as reported in these financial results were neither reviewed nor subject to audit, However, the management has exercised necessary due diligence to ensure that the financial results for these periods provide a true and fair view of the Company's affairs.

3. The Company has granted 70,317 ESOPs to its employees and 865,587 to the employees of its subsidiaries under Employee stock option and Share plan 2021 after taking necessary approval at an exercise price of Rs 232 per option on 22nd November 2021. These options will vest over a period of 1-4 years. Accordingly, the group has recorded a cost of INR 29.95 million during the quarter ended 31 December 2021.

4. During the quarter ended 31 December 2021,the Company has approved and converted the Compulsory convertible preference shares of Series A, Series B, Series B1, Series B2, Series C1 and Series C2 into equity shares of the Company in the ratio of 1:5.

5. The Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 Million and an offer for sale of 7,826,626 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. The Company has incurred Rs. 635.28 million as IPO related expenses which are proportionately allocated between the Company and Selling Shareholders as per respective offer size. The Company's share of these expenses amounting to Rs. 258.34 million has been adjusted against Securities Premium. Subsequently on 23rd December 2021, the equity shares of the Company have been listed on the BSE Limited and National Stock Exchange of India Limited. As at December 31 2021, the whole IPO proceeds were lying in the Company's bank account.

6. The management believes that the outbreak of COVID pandemic does not have any significant impact on the future operations of the Group since it provides essential services i.e., pathological testing services and sale of pharmaceutical items. Accordingly, the company continues to prepare the financial results on a going concern basis. Basis management's current assessment, it does not expect any adjustments to the carrying amounts of inventories, tangible assets, intangible assets, trade receivables and other financial assets on account of the current economic situation. The eventual outcome of the impact of this global health pandemic may be different from those estimated as on the date of approval of these consolidated financial results.

7. Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April 2021.

8. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

Place: Hyderabad
Date: 14 February 2022

For and on behalf of the Board of Directors of
MedPlus Health Services Limited
(formerly known as MedPlus Health Services Private Limited)

G.Madhukar Reddy
Managing Director
DIN: 00098097

MEDPLUS HEALTH SERVICES LIMITED
HYDERABAD

MedPlus Health Services Limited (formerly known as MedPlus Health Services Private Limited)
Regd. Office: 707, 7th Floor, 5-9-13 Taramandal Commercial Complex, Saifabad, Hyderabad - 500004, Telangana, India
CIN - U85110TG2006PLC051845
Extract of Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine months ended 31st December, 2021

Rs.In Millions

SL No.	Particulars	Standalone			Consolidated		
		Quarter ended		Nine months ended	Quarter ended		Nine months ended
		31 December 2021	31 December 2020	31 December 2021	31 December 2021	31 December 2020	31 December 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1	Total Income	258.33	211.09	1,102.24	9,407.87	8,097.72	28,316.86
2	Net Profit for the period (before tax and exceptional items)	(12.14)	26.52	46.56	217.51	320.01	1,053.08
3	Net Profit for the period (before tax and after exceptional items)	(12.14)	26.52	46.56	217.51	320.01	1,053.08
4	Net Profit for the period (after tax and exceptional items)	(12.14)	26.52	46.56	169.17	227.59	832.84
5	Total Comprehensive Income for the period (Comprising profit for the period (after tax) and Other Comprehensive Income (after tax)	(12.30)	25.03	46.94	167.68	220.18	849.31
6	Paid-up Capital:						
	(i) Equity Share Capital	238.60	1.94	238.60	238.60	1.94	238.60
	(ii) Compulsorily Convertible Preference Shares ('CCPS')	-	0.61	-	-	0.61	-
7	Earnings Per Share (Face value Rs. 2/- per share) (for continuing and discontinued operations) (not annualised)						
	Basic	(0.11)	0.26	0.42	1.53	2.21	7.66
	Diluted	(0.11)	0.25	0.42	1.52	2.12	7.44

Note:

1. The above is an extract of the detailed format of Standalone and Consolidated unaudited Financial Results filed with the Stock Exchanges under Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's website viz. www.medplusindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).

2. The above results of the Company have been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on February 14,2022

For and on behalf of the Board of Directors of
MedPlus Health Services Limited
(formerly known as MedPlus Health Services Private Limited

MEDPLUS HEALTH SERVICES LIMITED HYDERABAD

Date: 14 February 2022

G.Madhukar Reddy
Managing Director
DIN: 00098097